Conformis expects 50% drop in Q2 product revenue

July 6, 2020 By Sean Whooley

Joint replacement implant maker Conformis (NSDQ:CFMS) said today that it anticipates a COVID-19-influenced 50% year-over-year drop in second-quarter product revenue.

Releasing its preliminary results for the quarter ended June 30, the Billerica, Mass.-based company projected total revenue of $19.5 million for the quarter, which is down -1% year-over-year on a reported and constant currency basis. About half of that is made up of approximately $9.7 million in royalty revenue, including a royalty settlement of $9.6 million.

The other half was provided by $9.7 million in product revenue, which represents a 50% drop year-over-year. That total includes U.S. product revenue of approximately $8.3 million, which is down 52% from last year, and $1.4 million from the rest of the world, which is down 34% and 33$ on a reported basis and constant currency basis, respectively.

In March, Conformis announced that it was withdrawing its 2020 financial guidance while furloughing approximately 80 employees as a result of the COVID-19 pandemic and the deferral of elective procedures. In April, the company announced that it received more than $4.7 million through the U.S. Small Business Administration’s Paycheck Protection Program.

When reporting first-quarter losses in May, Conformis president & CEO Mark Augusti suggested that the second quarter would be heavily affected by the pandemic, even as elective procedures began to restart.

“As expected, the second quarter was impacted by the novel coronavirus pandemic,” Augusti said in a news release. “While we were pleased to see a fairly quick resumption of scheduled orthopedic procedures in May and June, we anticipate volumes to remain under pressure for the remainder of the year.

“It should be noted that we continue to withhold any comment about future performance. Clearly there was some correlation with the resumption of elective procedures; however, we cannot predict the pace of further resumption, the risk of further shutdowns in procedures and the geographic and regional uncertainty.”

Conformis also announced that it successfully amended its quarterly financial covenants in its loan and security agreement from June 25, 2019, with Innovatus Life Sciences Lending Fund, East West Bank and other lenders.

“For companies with credit facilities, the impact of COVID-19 on business operations has undoubtedly made it difficult for many of them to satisfy some or all of their financial covenants,” Augusti said. “We reported on March 23, 2020, that we may not be able to meet our 2Q revenue covenant and would work with Innovatus to modify our credit facility. I am pleased that we have been able to come to an agreement that better reflects current economic realities. This is an indication of the good and cooperative partnership we have with Innovatus.”

Conformis will host a webcast and conference call on Wednesday, Aug. 5, to discuss the financial results for the second quarter.

Nortech Systems closing one plant, selling two others
Nortech Systems (NSDQ:NSYS) announced this week that it will shutter one manufacturing plant and sell two others to lease them back following a tough year for the business. Maple Grove, Minn.-based Nortech said Tuesday that it will close its plant in Merrifield, Minn., by December 31, 2020, and offer that plant’s 60 employees jobs at its… […]
CMS proposes coverage updates that could increase access to VADs
The Centers for Medicare & Medicaid Services (CMS) today proposed coverage policy updates meant to increase access to VADs and artificial hearts. The policy updates, if approved, could be good news for major VAD makers Abbott (NYSE:ABT) and Medtronic (NYSE:MDT) — as well as people with heart failure who are waiting for a heart transplant or don’t… […]
Exceeding regulatory requirements: Beyond the checklist
Many manufacturers run into issues as they adjust their devices and testing plans to meet updated regulatory requirements. Using a risk-based approach to predict and mitigate risks can help prevent costly setbacks. Sherry Parker, WuXi AppTec Between the EU Medical Device Regulation (MDR) delay and other regulatory bodies shifting priorities due to COVID-19, manufacturers are… […]
FDA medical device user fees to increase 7% in 2021
By Stewart Eisenhart, Emergo Group The US Food and Drug Administration plans a 7% medical device user fee increases for the 2021 fiscal year, raising costs slightly for premarket submissions including 510(k) Premarket Notifications, Premarket Authorizations (PMA) and De Novo requests for classification. Get the full story here at the Emergo Group’s blog. The opinions… […]
MedAcuity advising Ventilator Project on software
MedAcuity Software (Westford, Mass.) announced today that it has volunteered to provide technical software assessment for The Ventilator Project, a non-profit working on developing a low-cost ventilator specifically for COVID-19 patients. Founded in March 2020 by entrepreneur Tyler Mantel of Watertower Robotics, The Ventilator Project has built a team of more than 250 volunteers from… […]
Hologic applies for pooled COVID-19 testing nod
Hologic (NSDQ:HOLX) announced today that it has self-validated use of its Aptima and Panther Fusion molecular diagnostic COVID-19 assays with pooled patient samples and applied for an FDA emergency use authorization (EUA) for pooled testing. Marlborough, Mass.-based Hologic is the third major company to announce it is seeking such authorization. Quest Diagnostics (NYSE:DGX) gained a pooled-sample testing EUA in July,… […]
Canon Medical launches mobile digital X-ray platform
Canon Medical Systems USA announced that it has launched a mobile digital X-ray system designed to streamline bedside exams to help improve workflow and productivity. The FDA 510(k)-cleared Soltus 500 has a compact design with features that promote efficiency and patient safety, without compromising image quality. They include: Intuitive tubehead controls, including an 8.4-in. touchscreen… […]
Electronic Valve Technology
The following is an overview of different technologies available when selecting the correct electronic valve for your application. Spider Valve Technology Invented and patented by Clippard, this deceptively simple design features only one moving part with a mere 0.007″ of travel. The spider is an armature spring that undergoes a variety of proprietary processes, including… […]
FDA opens umbrella authorization for surgical masks
Faced with a growing number of coronavirus cases and a shortage of personal protective equipment (PPE), the FDA has extended emergency use authorizations (EUAs) to certain surgical masks that are not protective against small airborne particles. Unlike N95 and some KN95 respirators, these masks “may be effective in blocking splashes and large particle droplets,” the… […]
Medtech and COVID-19: 7 things you need to know
When COVID-19 set upon the U.S. in March, medtech executives only had a month at most to explain to analysts in quarterly calls how the pandemic was hitting their companies — not nearly enough time to understand the long-term impact. Three more months have passed since those quarterly calls, and we’re now wrapping up a… […]
Report: Will Dr. Hahn crack under political pressure?
Many jobs have come with increased stress levels during the coronavirus pandemic, from ICU staff to Walmart greeters. Now officials who’ve been keeping tabs on FDA commissioner Dr. Stephen Hahn are wondering whether he can weather the strain of defending science while working for the Trump administration, according to a New York Times report. Hahn… […]

Conformis expects 50% drop in Q2 product revenue

In case you missed it

From Medical Design & Outsourcing

MASSDEVICE MEDICAL NETWORK

MASSDEVICE